Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Most GLP-1 providers cite ranges and vague claims. We cite the exact source: semaglutide produced a 14.9% average body weight reduction in the STEP 1 trial (Wilding et al., NEJM 2021, n=1,961). Tirzepatide produced up to 22.5% in the highest-dose group of SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539). These are not best-case figures — they are trial averages published in the world's most rigorous peer-reviewed medical journal.
The industry shows before-and-after photos at month 6. The clinical trials ran 68 to 72 weeks for a reason — that is how long it takes to reach maximum effect. Initial measurable loss begins at weeks 4–8. The plateau you will experience at months 4–6 is normal and documented. Your RealityPeptides physician will walk you through the documented progression curve at your honest intake, not after you have already started.
Every RealityPeptides prescription is reviewed and signed by a board-certified physician who reads your actual health data — your BMI, medical history, current medications, and contraindications. If GLP-1 therapy is not appropriate for you, we will tell you that honestly. If it is, you receive the medication that matches your real clinical profile, not the one with the highest commission margin.
Complete our comprehensive medical intake: weight, BMI, full medical history, current medications, and health goals. Your data is reviewed by a real board-certified physician — not an algorithm — who will give you an honest, frank assessment of whether GLP-1 therapy is right for you, which medication fits your profile, and what outcomes the trial data says you can realistically expect.
Based on your real health profile, your physician prescribes the appropriate GLP-1 medication — semaglutide, tirzepatide, or liraglutide — with a dosing schedule calibrated to your body and documented expectations. You receive a written summary of the clinical evidence behind your prescription and exactly what outcomes the data supports at your starting point.
Your FDA-approved GLP-1 medication ships from a PCAB-accredited pharmacy to your door within 2–5 business days. Regular telehealth check-ins track your documented progress against the trial benchmarks. If your results differ from expectations, your physician adjusts your plan honestly — no hiding the data, no false reassurance.
Ozempic® / Wegovy® — NEJM 2021, n=1,961
STEP 1 data: 14.9% average body weight reduction at 68 weeks with weekly subcutaneous injection. Trial participants on semaglutide lost an average of 33.7 lbs from a mean starting weight of 232 lbs. This is a population average — your physician will give you a personalized projection based on your actual BMI and health data, not the headline number.
Start Real Semaglutide TherapyMounjaro® / Zepbound® — NEJM 2022, n=2,539
SURMOUNT-1 data: dual GIP/GLP-1 mechanism. At 10 mg, average weight reduction was 19.5%. At 15 mg, it was 20.9%. The highest-dose group achieved 22.5% over 72 weeks. Currently the highest-efficacy FDA-approved GLP-1 option available. Your physician will assess whether tirzepatide fits your clinical profile and contraindication history before prescribing.
Start Real Tirzepatide TherapySaxenda® — SCALE Trial, 56 weeks
SCALE trial data: 8% average body weight reduction at 56 weeks with daily subcutaneous injection. Liraglutide has over a decade of post-market real-world safety data — the longest track record of any GLP-1 for weight management. For patients where weekly injections are not preferred or tirzepatide is contraindicated, liraglutide remains a clinically well-supported, honest choice.
Start Real Liraglutide TherapyAdult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
RealityPeptides connects patients in every US state with board-certified physicians who prescribe GLP-1 medications based on your real health data and documented clinical evidence — not marketing claims. Find your state below.
Here are the actual peer-reviewed figures: In the STEP 1 trial published in the New England Journal of Medicine (2021, n=1,961), semaglutide produced an average 14.9% body weight reduction over 68 weeks. In SURMOUNT-1 (NEJM 2022, n=2,539), tirzepatide achieved 20.9% average reduction at the 15 mg dose, with the highest-dose group reaching 22.5% over 72 weeks. In the SCALE trial, liraglutide achieved approximately 8% over 56 weeks. These are trial averages — your individual result will vary based on your health profile, adherence, and starting weight.
Most patients experience initial, measurable weight loss within 4 to 8 weeks of starting GLP-1 therapy. However, the significant results seen in clinical trials — the 15–22% figures — are reached at 12 to 18 months of consistent treatment. It is not a fast fix: the medication works by gradually resetting your appetite and metabolic signals. Patients who expect overnight transformation are frequently disappointed. Patients who commit to the full protocol with realistic milestones are the ones who achieve meaningful, lasting outcomes.
The honest answer: research shows that a significant portion of weight is regained after stopping GLP-1 therapy. A 2022 withdrawal study following STEP 1 found that participants regained approximately two-thirds of the weight lost within one year of stopping semaglutide. GLP-1 medications manage the biological drivers of obesity — they do not permanently reprogram them. Your physician will discuss long-term maintenance strategies, including continued low-dose therapy or structured tapering, based on your actual health data and goals.
Real-world and clinical trial data consistently show the most common side effects are gastrointestinal: nausea (reported in up to 44% of semaglutide patients in STEP 1), vomiting, diarrhea, and constipation. These are most intense during the dose-escalation phase and typically diminish over weeks 4–12. Less common but documented risks include gallbladder disease, pancreatitis, and acute kidney injury. There is a Black Box Warning for thyroid C-cell tumors based on animal studies. Serious adverse events are rare, but they are real — and your prescribing physician will review the complete risk/benefit profile with you honestly before you start.
Start with the trial averages as your benchmark, not the best-case outliers. The average in STEP 1 was 14.9% — that means roughly half of participants lost more, and half lost less. At 200 lbs, that is approximately 30 lbs over 68 weeks, or about 0.4 lbs per week. Pair that expectation with an honest assessment of your diet, activity level, and medical history. Our board-certified physicians do not tell you what you want to hear — they review your real health data and set a personalized, evidence-based projection before you begin.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
